David holds a PhD in Biological Sciences from Columbia University in New York, NY, where he studied how Drosophila ovarian adult stem cells respond to cell signaling pathway manipulations. As a Graduate Student and Postdoctoral Fellow at Columbia, his work helped redefine the organizational principles underlying adult stem cell growth models. He is currently a Science Writer, as part of the BioNews Services writing team.
Low expression levels of the protein TXNIP — thioredoxin interacting protein — was associated with worse outcomes in people with acute myeloid leukemia (AML), according to the results of a ... Read more
Jazz Pharmaceuticals, with help from the Myelodysplastic Syndrome (MDS) Foundation and the Cancer Support Community, has launched Find the Right Fit, an initiative providing educational resources about MDS and secondary ... Read more
The first patient has been dosed in a Phase 1 trial investigating the small molecule CA-4948 as a treatment for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes ... Read more
A completed Phase 1/2 clinical trial has shown encouraging results for Medigene‘s immune cell vaccine — which uses dendritic cells to “educate” T-cells about their targets — in people with ... Read more
The first patient has been dosed in a Phase 2 clinical trial examining Tolero Pharmaceuticals‘ investigational CDK9 inhibitor alvocidib as treatment for people with acute myeloid leukemia (AML) who failed ... Read more
Sellas Life Sciences has started screening acute myeloid leukemia (AML) patients for a Phase 3 clinical trial evaluating its experimental vaccine galinpepimut-S (GPS) as a second-line maintenance therapy for patients who ... Read more